» Articles » PMID: 34106323

Catheter Ablation of Supraventricular Tachycardia in Patients with and Without Structural Heart Disease: Insights from the German Ablation Registry

Abstract

Aim: To compare patient characteristics, safety and efficacy of catheter ablation of supraventricular tachycardia (SVT) in patients with and without structural heart disease (SHD) enrolled in the German ablation registry.

Methods And Results: From January 2007 until January 2010, a total of 12,536 patients (37.2% with known SHD) were enrolled and followed for at least one year. Patients with SHD more often underwent ablation for atrial flutter (45.8% vs. 20.9%, p < 0.001), whereas patients without SHD more often underwent ablation for atrioventricular nodal reentrant tachycardia (30.2% vs. 11.8%, p < 0.001) or atrioventricular reentrant tachycardia (9.1% vs. 1.6%, p < 0.001). Atrial fibrillation catheter ablation procedures were performed in a similar proportion of patients with and without SHD (38.1% vs. 36.9%, p = 0.21). Overall, periprocedural success rate was high in both groups. Death, myocardial infarction or stroke occurred in 0.2% and 0.1% of patients with and without SHD (p = 0.066). Major non-fatal complications prior to discharge were rare and did not differ significantly between patients with and without SHD (0.5% vs. 0.4%, p = 0.34). Kaplan-Meier mortality estimate at 1 year demonstrated a significant mortality increase in patients with SHD (2.6% versus 0.7%; p < 0.001).

Conclusion: Patients with and without SHD undergoing SVT ablation exhibit similar success rates and low major complication rates, despite disadvantageous baseline characteristics in SHD patients. These data highlight the safety and efficacy of SVT ablation in patients with and without SHD. Nevertheless Kaplan-Meier mortality estimates at 1 year demonstrate a significant mortality increase in patients with SHD, highlighting the importance of treating the underlying condition and reliable anticoagulation if indicated.

Citing Articles

Characteristics of Patients Undergoing Electrophysiologic Procedures in a Tertiary Hospital in Saudi Arabia.

Aljammaz A, Alghanim M, Altamimi I, Alshwieer M, Sabbagh A, Alsayed A J Saudi Heart Assoc. 2024; 35(4):346-353.

PMID: 38226071 PMC: 10789185. DOI: 10.37616/2212-5043.1362.


Right coronary artery compromise following radiofrequency catheter ablation for supraventricular tachycardia: cases reports.

Young W, Vyas S, Wragg A, Sporton S, Rosengarten J, Schilling R Eur Heart J Case Rep. 2023; 7(9):ytad411.

PMID: 37743895 PMC: 10516517. DOI: 10.1093/ehjcr/ytad411.


Acute and mid-term outcomes of ablation for atrial fibrillation with VISITAG SURPOINT: the Japan MIYABI registry.

Okumura K, Inoue K, Goya M, Origasa H, Yamazaki M, Nogami A Europace. 2023; 25(9).

PMID: 37490850 PMC: 10492225. DOI: 10.1093/europace/euad221.


Sex and racial disparities in catheter ablation.

Vandenberk B, Chew D, Parkash R, Gillis A Heart Rhythm O2. 2023; 3(6Part B):771-782.

PMID: 36589007 PMC: 9795271. DOI: 10.1016/j.hroo.2022.08.002.

References
1.
Kuck K, Merkely B, Zahn R, Arentz T, Seidl K, Schluter M . Catheter Ablation Versus Best Medical Therapy in Patients With Persistent Atrial Fibrillation and Congestive Heart Failure: The Randomized AMICA Trial. Circ Arrhythm Electrophysiol. 2019; 12(12):e007731. DOI: 10.1161/CIRCEP.119.007731. View

2.
Katritsis D, Boriani G, Cosio F, Hindricks G, Jais P, Josephson M . European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y.... Eur Heart J. 2016; 39(16):1442-1445. DOI: 10.1093/eurheartj/ehw455. View

3.
Morka A, Sledz J, Deutsch K, Ludwik B, Zagrodzka M, Szydlowski L . Feasibility and performance of catheter ablation with zero-fluoroscopy approach for regular supraventricular tachycardia in patients with structural and/or congenital heart disease. Medicine (Baltimore). 2019; 98(41):e17333. PMC: 6799864. DOI: 10.1097/MD.0000000000017333. View

4.
Wilke I, Witzel K, Munch J, Pecha S, Blankenberg S, Reichenspurner H . High Incidence of De Novo and Subclinical Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy and Cardiac Rhythm Management Device. J Cardiovasc Electrophysiol. 2016; 27(7):779-84. DOI: 10.1111/jce.12982. View

5.
OHara G, Philippon F, Champagne J, Blier L, Molin F, Cote J . Catheter ablation for cardiac arrhythmias: a 14-year experience with 5330 consecutive patients at the Quebec Heart Institute, Laval Hospital. Can J Cardiol. 2007; 23 Suppl B:67B-70B. PMC: 2794475. DOI: 10.1016/s0828-282x(07)71013-9. View